v3.24.2
SUPPLEMENTAL INFORMATION
 6 Months Ended
Jun. 30, 2024
Geographic Areas, Long-Lived Assets [Abstract]  
Supplemental information SUPPLEMENTAL INFORMATION
The Company operates in a single reportable segment.
The following table presents long-lived assets by location:
June 30,
2024		December 31,
2023
 UnauditedAudited
United States$50,124 $41,634 
Israel8,449 8,317 
Switzerland13,620 7,733 
Others6,003 5,179 
Total long lived assets$78,196 $62,863 

Restructuring
In November 2023, the Company announced a series of actions to strengthen and optimize its business operations to support near-term growth drivers and long-term value creation. The plan included a reduction in headcount of approximately 200 employees or 13% of the Company's then current workforce. The Company incurred restructuring costs (including severance pay, garden leave payments, etc.) for the three and six months ended June 30, 2024 and the year ended December 31, 2023, as follows:
Three months ended June 30,Six months ended June 30,Year ended December 31,
2023
2024202320242023
UnauditedUnauditedAudited
Cost of revenues$— $— $52 $— $262 
Research, development and clinical studies— — 275 — 2,070 
Sales and marketing(27)— 1,512 — 2,404 
General and administrative— — 164 — 1,495 
Total restructuring cost
$(27)$— $2,003 $— $6,231 
Restructuring costs paid during the period
$327 $— $5,455 $— $2,753 

These restructuring costs were offset by accrual reversals for the three and six months ended June 30, 2024 and the year ended December 31, 2023 in the amount of $0, $369 and $3,041, respectively, which relate to the terminated employees' exits from the Company’s cash incentive plans. These restructuring costs were further offset by forfeited equity-based compensation expense reversals for the three and six months ended June 30, 2024 and the year ended December 31, 2023 in the amount of $330, $1,991 and $9,313, respectively, which relate to the terminated employees' exits from the Company’s equity incentive plan.